Free tool · No signup

Kidney disease treatment & trial finder

Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.

For information only — not medical advice. Always talk to your nephrologist.

Kidney treatment is advancing fast

17 FDA-approved therapies since 2018 8 in the last two years — plus 3 trials enrolling now.

17
Approved therapies
3
Trials enrolling
9
Conditions covered
1
1
5
1
1
6
2
18
19
20
21
22
23
24
25
26

New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.

Type
Common conditions

Treatment Options for Your Diagnosis

1

Foundational care

Start here

Blood-pressure control with ACE inhibitors or ARBs, and SGLT2 inhibitors, are standard first-line therapy for most CKD. Your nephrologist typically starts here.

These are newer and recently approved therapies for FSGS (focal segmental glomerulosclerosis) — not the full standard of care. Ask your care team whether any fit your situation.

Travere Therapeutics logo
Travere Therapeutics
Sparsentan (Filspari)
FDA approved

Dual endothelin-A and angiotensin-II receptor antagonist

DUPLEX

Approved treatment: Approved (April 2026) for reducing proteinuria in patients age 8+ with FSGS without nephrotic syndrome. Commercially available by prescription in the U.S.

Evidence: In the Phase 3 DUPLEX study, sparsentan produced a greater reduction in proteinuria than irbesartan, although the original 108-week eGFR slope endpoint was not statistically significant.

View the DUPLEX study on ClinicalTrials.gov

Source: FDA prescribing information (Filspari); DUPLEX, NEJM 2024Verified 2026-07-18

Clinical Trials Related to Your Diagnosis

Actively enrolling studies related to FSGS (focal segmental glomerulosclerosis). Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.

No actively enrolling trials we're tracking for FSGS (focal segmental glomerulosclerosis) right now.

Browse all recruiting FSGS (focal segmental glomerulosclerosis) trials on ClinicalTrials.gov

For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.

Manage your whole kidney journey

Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.

Get started free